Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 4

Sponsor Class

INDUSTRY 4NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 2Tumor-Agnostic 1Genitourinary 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Prostatic Neoplasms 1Peritoneal Neoplasms 1Neoplasms 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × phenoxodiol × Clear all
NCT02941523 2021-06-02

Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours

Noxopharm Limited

Phase 1/2 Completed
19 enrolled 12 charts
Tumor-Agnostic

Neoplasms

NCT00382811 2016-07-18

OVATURE

MEI Pharma, Inc.

Phase 3 Completed
142 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00091377 2016-07-14

Phenoxodiol Combined With Either Cisplatin or Paclitaxel in Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

MEI Pharma, Inc.

Phase 1/2 Completed
65 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00557037 2010-04-08

A Phase II Trial of Phenoxodiol in Patients With Castrate and Non-Castrate Prostate Cancer

MEI Pharma, Inc.

Phase 2 Completed
60 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡